Related Experiment Video
Updated: Apr 12, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
[Metastasized prostate cancer. Position paper on the use of chemotherapy]
C-H Ohlmann1, S Duensing, R Eichenauer
1Klinik für Urologie und Kinderurologie, Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes, Kirrbergerstraße 1, 66424, Homburg, Deutschland, carsten.ohlmann@uks.eu.
Background:
Antihormonal and cytotoxic therapy options are available for the therapy of metastasized prostate cancer (mPC). Because no comparative studies are available, especially for castration-resistant prostate cancer (mCRCP), it remains unclear which patients will profit best from which therapy.
Objectives:
Previous data on the sequence of the various therapy options show that correct selection of the first line therapy for mCRPC can have an influence on the prognosis of the patient. In this position paper the various therapy options are critically illustrated and the clinical and pathohistological criteria for selection of the first line therapy of mCRPC are discussed.
Results:
Molecular markers are an important aid for future patient selection and individualized therapy for optimal use of the available forms of therapy.
